Literature DB >> 2453882

Selective elimination of idiotype-binding cells in vivo by a drug-idiotype conjugate demonstrates the functional significance of these cells in immune regulation.

M M Abu-Hadid1, R B Bankert, G L Mayers.   

Abstract

A receptor-specific cytotoxic drug delivery system has been used to eliminate idiotype-binding cells in vivo to ascertain the possible functional significance of these cells in regulating the humoral immune response to dextran. Protein M104E, a mouse myeloma protein that binds dextran, expresses a private idiotope that is present on a significant proportion of the normal dextran-specific antibody repertoire. Immunocompetent cells that bind and internalize M104E idiotype-bearing molecules were eliminated by the intravenous administration of a single dose of cytosine arabinonucleoside conjugated to purified M104E protein. The administration of this cytotoxic drug-idiotype conjugate had a profound effect upon the expression of the M104E idiotype in euthymic but not in athymic BALB/c mice following immunization with dextran. In euthymic mice, the depletion of the idiotype-binding cells resulted in a marked elevation in the level of M104E idiotype present in the immune sera. Moreover, treated but not control mice developed idiotype-positive molecules that did not bind dextran. These results demonstrate the functional significance of idiotype-binding cells in the regulation of individual clonotypes during an immune response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453882      PMCID: PMC280346          DOI: 10.1073/pnas.85.11.3990

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Detection of anti-idiotype reactive cells in the response to phosphorylcholine.

Authors:  H Cosenza
Journal:  Eur J Immunol       Date:  1976-02       Impact factor: 5.532

2.  Immunological function of the thymus.

Authors:  J F MILLER
Journal:  Lancet       Date:  1961-09-30       Impact factor: 79.321

3.  Modification of immunoglobulin G using specific reactivity of sugar moiety.

Authors:  A Murayama; K Shimada; T Yamamoto
Journal:  Immunochemistry       Date:  1978-08

4.  Specific inactivation of antigen-reactive cells with 125I-labelled antigen.

Authors:  G L Ada; P Byrt
Journal:  Nature       Date:  1969-06-28       Impact factor: 49.962

Review 5.  Expression and function of idiotypes of lymphocytes.

Authors:  K Eichmann
Journal:  Adv Immunol       Date:  1978       Impact factor: 3.543

6.  Avian antigen-binding cells. I. Characterization of antigen-binding T cells from bursectiomized chickens by autoradiography.

Authors:  G Higgins; Y S Choi
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

7.  Antigen- and receptor-driven regulatory mechanisms. VII. H-2-restricted anti-idiotypic suppressor factor from efferent suppressor T cells.

Authors:  M H Dietz; M S Sy; B Benacerraf; A Nisonoff; M I Greene; R N Germain
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

8.  Receptor-blocking factor present in immune serum resembling auto-anti-idiotype antibody.

Authors:  R B Bankert; D Pressman
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

9.  Immunoregulation of localized and disseminated murine myeloma: antigen-specific regulation of MOPC-315 stem cell proliferation and secretory cell differentiation.

Authors:  J W Rohrer; R G Lynch
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

10.  Presence on idiotype-specific suppressor T cells of receptors that interact with molecules bearing the idiotype.

Authors:  F L Owen; S T Ju; A Nisonoff
Journal:  J Exp Med       Date:  1977-06-01       Impact factor: 14.307

View more
  1 in total

1.  Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.

Authors:  G B Sivolapenko; C Moreno; W Smith; J Corválan; M A Ritter; A A Epenetos
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.